Trial Profile

A Combined Single Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of NNZ-2591 in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NNZ 2591 (Primary)
Indications Neurodevelopmental disorders; Telomeric 22q13 Monosomy Syndrome
Focus Adverse reactions; First in man
Sponsors Neuren Pharmaceuticals

Most Recent Events

28 Jun 2021 Status changed from recruiting to completed.
14 May 2020 New source identified and integrated: ClinicalTrials.gov: US National Institutes of Health (NCT04379869).
07 May 2020 Status changed from planning to recruiting, according to an Neuren Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com